Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Assets: 2023-2025

Historic Assets for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $299.4 million.

  • Immunome's Assets rose 16.54% to $299.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.4 million, marking a year-over-year increase of 16.54%. This contributed to the annual value of $240.2 million for FY2024, which is 61.73% up from last year.
  • As of Q3 2025, Immunome's Assets stood at $299.4 million, which was up 1.04% from $296.3 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Assets peaked at $342.7 million during Q1 2025, and registered a low of $41.4 million during Q2 2023.
  • For the 3-year period, Immunome's Assets averaged around $216.6 million, with its median value being $256.9 million (2024).
  • Data for Immunome's Assets shows a peak YoY soared of 614.89% (in 2024) over the last 5 years.
  • Immunome's Assets (Quarterly) stood at $148.5 million in 2023, then surged by 61.73% to $240.2 million in 2024, then grew by 16.54% to $299.4 million in 2025.
  • Its Assets stands at $299.4 million for Q3 2025, versus $296.3 million for Q2 2025 and $342.7 million for Q1 2025.